Servier Just Paid $2.65 Billion for a Drug That Hasn't Hit Phase 3 Results Yet

That gap is exactly where sevasemten is trying to land.

Sevasemten: The Drug Worth Billions

Sevasemten is an oral drug, which already makes it stand out in a field where many therapies require infusions or gene therapy. It's being developed for two forms of muscular dystrophy: Becker (the milder, slower cousin) and Duchenne (the more severe form that typically appears in early childhood).

For Becker muscular dystrophy, sevasemten is in a Phase 3 trial called GRAND CANYON. The topline results from that study are expected in Q4 2026, making this the single biggest catalyst on the horizon. Earlier data, though, has been encouraging. In a long-term open-label extension study called MESA, patients showed sustained functional stabilization for up to 3.5 years. In a disease where steady decline is the norm, stabilization is like watching a ball stop rolling downhill.

For Duchenne, the program is earlier (Phase 2), with two ongoing studies called LYNX and FOX testing sevasemten in children. The Phase 2 data showed the drug was well tolerated and helped identify a 10 mg dose for a future Phase 3 study. Think of these trials as the audition before the main performance.

Servier's Bigger Bet on Rare Disease

This isn't a random shopping spree. Servier has been methodically building a rare neurological disease portfolio as part of its Servier 2030 strategy. The company has flagged neuromuscular disorders, refractory epilepsy, autism spectrum disorders, and movement disorders as priority areas.

The Edgewise acquisition is the biggest, most concrete move in that plan so far. Rather than chasing blockbuster drugs for massive patient populations, Servier is targeting well-defined groups of patients with few or no good options. It's the difference between opening a massive chain restaurant and running a Michelin-starred spot with 30 seats; smaller audience, but the demand is intense and the competition is thin.

For a privately held French company (Servier doesn't have public shareholders to please every quarter), this kind of long-game strategy makes sense. They can afford to be patient.

Wall Street's Verdict on Edgewise

Edgewise's stock tells an interesting story. Analysts have a Moderate Buy consensus with price targets clustering around $47 to $49. Leerink bumped its target to $52 after the asset sale announcement plus positive data from the cardiac pipeline.

But not everyone's throwing confetti. Morningstar pegged Edgewise's fair value at just $23.22 with "high uncertainty," suggesting the current price already bakes in a lot of optimism about the remaining cardiovascular programs. The stock's price-to-book ratio of 4.7x is well below the peer average of 46.7x, which means the market is pricing Edgewise for meaningful pipeline success without going full speculative fever dream.

The tension is clear: bulls see a company that just banked $1.55 billion in cash and still has a promising heart drug portfolio. Bears see a biotech that just sold its most advanced asset and now has to prove the cardiac story on its own.

The $2.65 Billion Question

Everything comes down to GRAND CANYON. If the Phase 3 data for sevasemten in Becker muscular dystrophy hits later this year and confirms what the earlier studies suggested, Servier's deal will look like a steal. The company would have a first-in-class oral therapy for a disease with virtually no competition, backed by 3.5 years of stabilization data.

If the data disappoints? Servier still has the Duchenne program and the earlier-stage assets, but the $1.55 billion upfront starts looking a lot more expensive.

For muscular dystrophy patients, though, the deal itself is a signal worth celebrating. When a major pharma company bets billions on your disease, it means the field is finally getting the investment it deserves. After decades of waiting, that's not nothing.

The Flu Shot Just Got Its Biggest Upgrade in Decades

The FDA just approved the first-ever mRNA flu vaccine, and it beat traditional shots in a 41,000-person trial. Moderna's mFlusiva won't make much money this year, but it might reshape a $9 billion market.